IIPM BEST B-SCHOOL
As Ranbaxy confirmed to B&E, “We have a balanced business model... Ranbaxy’s US product pipeline is valued at over $40 billion (at innovator brand prices).” The company has now even joined hands with a number of international corporations for joint marketing and joint development activities, especially in the light advanced technologies and techniques not accessible solely to a particular company. Not only this, Malvinder M Singh, CEO & MD, Ranbaxy, has already acquired five entities since having taken over the top mantle last year from Brian Tempest. The acquisition drive has been built on strong foundations such as the $324 million acquisition of Terapia, a Romanian company, and the 2006 takeover of Glaxo Smithkline’s generic products businesses in western Europe.
Malvinder aspires to be “amongst the top five (global) generic players... and to attain a turnover of $5 billion by 2012!” With manufacturing bases in eight countries, with more than 10,000 employees worldwide, with many more countries being targeted for growing their businesses, and with increasing orientation towards having a passionate global vision, Ranbaxy qualifies at the numero uno position in the B&E Power 100 healthcare sector rankings... Undoubtedly ‘patiently’!
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2006, Arindam Chaudhuri's Initiative
For More IIPM Article, Visit Below....
IIPM MANAGEMENT INSTITUTE
IIPM Academics : Global Outreach Program
IIPM Students Life > Campus Resources
IIPM Alliances
IIPM Students Life > Campus Placement
IIPM Academics : Curriculum
IIPM RANKED AHEAD OF FIVE OF THE IIMS RATED AS...
The Diwali range (of Barista) will be targeted at...
To the Highlands of Heaven!
As Ranbaxy confirmed to B&E, “We have a balanced business model... Ranbaxy’s US product pipeline is valued at over $40 billion (at innovator brand prices).” The company has now even joined hands with a number of international corporations for joint marketing and joint development activities, especially in the light advanced technologies and techniques not accessible solely to a particular company. Not only this, Malvinder M Singh, CEO & MD, Ranbaxy, has already acquired five entities since having taken over the top mantle last year from Brian Tempest. The acquisition drive has been built on strong foundations such as the $324 million acquisition of Terapia, a Romanian company, and the 2006 takeover of Glaxo Smithkline’s generic products businesses in western Europe.
Malvinder aspires to be “amongst the top five (global) generic players... and to attain a turnover of $5 billion by 2012!” With manufacturing bases in eight countries, with more than 10,000 employees worldwide, with many more countries being targeted for growing their businesses, and with increasing orientation towards having a passionate global vision, Ranbaxy qualifies at the numero uno position in the B&E Power 100 healthcare sector rankings... Undoubtedly ‘patiently’!
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2006, Arindam Chaudhuri's Initiative
For More IIPM Article, Visit Below....
IIPM MANAGEMENT INSTITUTE
IIPM Academics : Global Outreach Program
IIPM Students Life > Campus Resources
IIPM Alliances
IIPM Students Life > Campus Placement
IIPM Academics : Curriculum
IIPM RANKED AHEAD OF FIVE OF THE IIMS RATED AS...
The Diwali range (of Barista) will be targeted at...
To the Highlands of Heaven!
No comments:
Post a Comment